# Prudentia Sciences

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/prudentia-sciences

- Industry: Software
- Headquarters: Cambridge, US
- Website: www.prudentiasciences.com
- Total disclosed funding: $20M
- Latest round: Series A (Jan 7, 2026)
- Investors on record: 5

## About

Founded in 2023 and based in Massachusetts, US, Prudentia Sciences, Inc. specializes in AI-driven decision support for the biopharma industry. The company was founded by its CEO, Sadiqa Mahmood. In January 2026, Prudentia Sciences, Inc. raised USD 20 million in series A funding led by McKesson Ventures, with participation from SignalFire, Iaso Ventures, Virtue Venture Management and GV also participated in the round.

Prudentia Sciences offers an artificial intelligence-powered asset diligence and valuation platform designed to enhance decision-making in the biopharma sector through AI-powered asset diligence and valuation. The core product suite focuses on providing data-driven insights that empower biopharma companies and investors to optimize their drug development pipelines and capital allocation strategies. The company leverages AI and human expertise to analyze drug assets.

The company plans to utilize the funding raised in January 2026 to expand product capabilities, enhance diligence intelligence, and scale commercial operations, including growth in Asia-Pacific and Europe.

## Funding rounds

- Series A, Jan 7, 2026, $20M — GV, McKesson Ventures, SignalFire, Iaso Ventures, Virtue Venture Management

## Investors

- GV (https://capitalatlas.ai/funds/gv) — Series A
- McKesson Ventures (https://capitalatlas.ai/funds/mckesson-ventures) — Series A
- SignalFire (https://capitalatlas.ai/funds/signalfire) — Series A
- Iaso Ventures (https://capitalatlas.ai/funds/iaso-ventures) — Series A
- Virtue Venture Management (https://capitalatlas.ai/funds/virtue-venture-management) — Series A